301201 诚达药业
已收盘 12-20 15:00:00
资讯
新帖
简况
诚达药业：财通证券投资者于12月17日调研我司
证券之星 · 12-17
诚达药业：财通证券投资者于12月17日调研我司
诚达药业(301201.SZ)完成回购2.1%股份 耗资5706.16万元
智通财经 · 12-11
诚达药业(301201.SZ)完成回购2.1%股份 耗资5706.16万元
诚达药业：上海睿华资产管理有限公司投资者于12月9日调研我司
证券之星 · 12-09
诚达药业：上海睿华资产管理有限公司投资者于12月9日调研我司
美生物安全法案“生变”，CRO概念大举反攻，药明系嗨了！
格隆汇 · 12-09
美生物安全法案“生变”，CRO概念大举反攻，药明系嗨了！
诚达药业：因自身经营需要 股东前海晟泰投资拟减持不超638.49万股
中国财富通 · 11-22
诚达药业：因自身经营需要 股东前海晟泰投资拟减持不超638.49万股
诚达药业(301201.SZ)主要股东深圳前海晟泰投资企业(有限合伙)拟减持不超4.22%股份
智通财经 · 11-21
诚达药业(301201.SZ)主要股东深圳前海晟泰投资企业(有限合伙)拟减持不超4.22%股份
诚达药业最新公告：股东前海晟泰拟减持不超4.22%公司股份
证券之星 · 11-21
诚达药业最新公告：股东前海晟泰拟减持不超4.22%公司股份
诚达药业（301201）11月14日主力资金净买入1880.95万元
证券之星 · 11-15
诚达药业（301201）11月14日主力资金净买入1880.95万元
诚达药业(301201.SZ)：达格列净原料药通过CDE审批
智通财经 · 11-14
诚达药业(301201.SZ)：达格列净原料药通过CDE审批
诚达药业最新公告：达格列净原料药通过CDE审批
证券之星 · 11-14
诚达药业最新公告：达格列净原料药通过CDE审批
诚达药业：达格列净原料药上市申请获批
美港电讯 · 11-14
诚达药业：达格列净原料药上市申请获批
诚达药业(301201.SZ)累计回购2.1%股份 耗资5706.16万元
智通财经 · 11-05
诚达药业(301201.SZ)累计回购2.1%股份 耗资5706.16万元
诚达药业（301201）2024年三季报简析：净利润减33.98%，公司应收账款体量较大
证券之星 · 10-30
诚达药业（301201）2024年三季报简析：净利润减33.98%，公司应收账款体量较大
图解诚达药业三季报：第三季度单季净利润同比减52.19%
证券之星 · 10-29
图解诚达药业三季报：第三季度单季净利润同比减52.19%
诚达药业(301201.SZ)发布前三季度业绩，净利润4039.28万元，下降33.98%
智通财经 · 10-28
诚达药业(301201.SZ)发布前三季度业绩，净利润4039.28万元，下降33.98%
诚达药业(301201)9月30日股东户数1.47万户，较上期减少1.65%
证券之星 · 10-28
诚达药业(301201)9月30日股东户数1.47万户，较上期减少1.65%
诚达药业：10月23日接受机构调研，国信证券、跬步投资等多家机构参与
证券之星 · 10-23
诚达药业：10月23日接受机构调研，国信证券、跬步投资等多家机构参与
10月22日诚达药业现1笔折价21.48%的大宗交易 合计成交712.32万元
证券之星 · 10-22
10月22日诚达药业现1笔折价21.48%的大宗交易 合计成交712.32万元
诚达药业10月21日现1笔大宗交易 成交金额403.2万元
新浪证券-红岸工作室 · 10-21
诚达药业10月21日现1笔大宗交易 成交金额403.2万元
10月14日诚达药业现1笔折价21.91%的大宗交易 合计成交731.14万元
证券之星 · 10-14
10月14日诚达药业现1笔折价21.91%的大宗交易 合计成交731.14万元
加载更多
公司概况
公司名称：
诚达药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-20
主营业务：
诚达药业股份有限公司主要致力于为跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO服务，并从事左旋肉碱系列产品的研发、生产和销售。公司主要产品及服务是预临床及临床阶段新药CDMO服务、已上市药物CDMO服务、仿制药中间体CDMO服务、食品添加剂、饲料添加剂、原料药。公司是国内最早实现左旋肉碱系列产品产业化的企业之一，也是全球左旋肉碱主要供应商之一。产品产业链齐全，包括食品添加剂、饲料添加剂、原料药，产品出口全球30多个国家和地区。
发行价格：
72.69
{"stockData":{"symbol":"301201","market":"SZ","secType":"STK","nameCN":"诚达药业","latestPrice":22.07,"timestamp":1734678231000,"preClose":21.8,"halted":0,"volume":1688780,"delay":0,"floatShares":87193799,"shares":155000000,"eps":0.4537,"marketStatus":"已收盘","marketStatusCode":5,"change":0.27,"latestTime":"12-20 15:00:00","open":21.67,"high":22.2,"low":21.67,"amount":37167400,"amplitude":0.0243,"askPrice":22.07,"askSize":16,"bidPrice":22.05,"bidSize":53,"shortable":0,"etf":0,"ttmEps":0.4537,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734917400000},"adr":0,"adjPreClose":21.8,"symbolType":"stock","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":23.98,"lowLimit":19.62,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":154713824,"pbRate":1.51,"roa":"--","roe":"1.8%","epsLYR":0.5881,"committee":-0.446494,"marketValue":3415000000,"floatMarketCap":1924000000,"peRate":48.644478,"changeRate":0.0124,"turnoverRate":0.0194,"status":0},"requestUrl":"/m/hq/s/301201","defaultTab":"news","newsList":[{"id":"2492932183","title":"诚达药业：财通证券投资者于12月17日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2492932183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492932183?lang=zh_cn&edition=full","pubTime":"2024-12-17 18:33","pubTimestamp":1734431589,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月17日诚达药业发布公告称财通证券华挺 赵千于2024年12月17日调研我司。诚达药业主营业务：跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO研发生产服务,以及左旋肉碱系列产品、原料药的研发、生产和销售。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121700032333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","601108","BK0276","301201"],"gpt_icon":0},{"id":"2490460838","title":"诚达药业(301201.SZ)完成回购2.1%股份 耗资5706.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490460838","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490460838?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:41","pubTimestamp":1733906515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)公告，截至本公告披露日，公司通过股份回购专用证券账户以集中竞价交易方式累计回购公司股份数量324.47万股，占公司当前总股本的2.10%(以公司当前总股本154,713,824股计算)，最高成交价为22.21元/股，最低成交价为14.63元/股，成交总金额为5706.16万元(不含交易费用)，本次回购股份方案实施完毕。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301201"],"gpt_icon":0},{"id":"2490130723","title":"诚达药业：上海睿华资产管理有限公司投资者于12月9日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2490130723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490130723?lang=zh_cn&edition=full","pubTime":"2024-12-09 19:32","pubTimestamp":1733743976,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年12月9日诚达药业发布公告称上海睿华资产管理有限公司朱崇玮于2024年12月9日调研我司。公司左旋肉碱系列产品出口全球30多个国家，品质稳定，拥有良好的国际知名度，已成为全球左旋肉碱主要供应商之一。目前公司左旋肉碱产品销售价格相对稳定，较最低行情已略有好转，后续相关产品价格走势存仍存在一定的不确定性。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120900027016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09983","BK1583","BK1229","301201","BK1258","BK0239","BK1542"],"gpt_icon":0},{"id":"2490718823","title":"美生物安全法案“生变”，CRO概念大举反攻，药明系嗨了！","url":"https://stock-news.laohu8.com/highlight/detail?id=2490718823","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490718823?lang=zh_cn&edition=full","pubTime":"2024-12-09 12:10","pubTimestamp":1733717419,"startTime":"0","endTime":"0","summary":"行业悲观预期或好转","market":"us","thumbnail":"https://img3.gelonghui.com/25d53-cb9c4747-fd5c-4169-a43e-056e33d68b09.jpg?guru_height=718&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/25d53-cb9c4747-fd5c-4169-a43e-056e33d68b09.jpg?guru_height=718&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1449943","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0348735423.USD","LU0456846285.SGD","BK0081","BK1576","LU2039709279.SGD","LU2242644610.SGD","LU0819121731.USD","LU0572944931.SGD","LU0823426480.USD","BK1521","BK0086","301201","NDAA","BK0077","SG9999002562.SGD","LU1880383366.USD","LU1794554557.SGD","LU2488822045.USD","000710","BK0102","LU0052750758.USD","300149","LU0456827905.SGD","BK0042","02268","LU0348825331.USD","BK1583","BK0028","02359","LU0823426308.USD","LU0359202008.SGD","BK0216","LU1997245177.USD","603259","LU1242518931.SGD","LU0856984785.SGD","LU0456842615.SGD","LU0327786744.USD","LU0307460666.USD","LU2045819591.USD","LU1688375341.USD","LU0051755006.USD","BK1141","LU0043850808.USD","LU1046422090.SGD","LU0516422366.SGD","SG9999014674.SGD","LU0359201612.USD","LU0320764599.SGD"],"gpt_icon":1},{"id":"2485404827","title":"诚达药业：因自身经营需要 股东前海晟泰投资拟减持不超638.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2485404827","media":"中国财富通","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485404827?lang=zh_cn&edition=full","pubTime":"2024-11-22 12:10","pubTimestamp":1732248606,"startTime":"0","endTime":"0","summary":"中国财富通11月22日 - 诚达药业（301201）公告称，持有公司股份17,391,840股（占本公司剔除回购专户股份数后总股本比例11.48%）的股东深圳前海晟泰投资企业（有限合伙），计划在本公告披露之日起15个交易日后的3个月内（2024年12月16日至2025年3月15日），以大宗交易方式减持本公司股份不超过6,384,943股（占本公司剔除回购专户股份数后总股本比例4.22%）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=EQRsFpITDNQ%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2485645484","title":"诚达药业(301201.SZ)主要股东深圳前海晟泰投资企业(有限合伙)拟减持不超4.22%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2485645484","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485645484?lang=zh_cn&edition=full","pubTime":"2024-11-21 19:39","pubTimestamp":1732189187,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)公告，公司持股5%以上股东深圳前海晟泰投资企业(有限合伙)计划在本公告披露之日起15个交易日后的3个月内(2024年12月16日至2025年3月15日)以大宗交易方式减持公司股份不超过638.49万股(占公司剔除回购专户股份数后总股本比例4.22%)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2485746437","title":"诚达药业最新公告：股东前海晟泰拟减持不超4.22%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2485746437","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485746437?lang=zh_cn&edition=full","pubTime":"2024-11-21 19:31","pubTimestamp":1732188668,"startTime":"0","endTime":"0","summary":"诚达药业公告，持股5%以上股东深圳前海晟泰投资企业（有限合伙）计划在本公告披露之日起15个交易日后的3个月内（2024年12月16日至2025年3月15日）以大宗交易方式减持公司股份不超过638.49万股（占公司剔除回购专户股份数后总股本比例4.22%）。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112100031556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"gpt_icon":0},{"id":"2483025366","title":"诚达药业（301201）11月14日主力资金净买入1880.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483025366","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483025366?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:11","pubTimestamp":1731633072,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年11月14日收盘，诚达药业报收于25.01元，上涨5.35%，换手率10.98%，成交量9.57万手，成交额2.38亿元。近5日资金流向一览见下表：诚达药业融资融券信息显示，融资方面，当日融资买入1885.15万元，融资偿还2228.81万元，融资净偿还343.67万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500007420.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"gpt_icon":0},{"id":"2483824275","title":"诚达药业(301201.SZ)：达格列净原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2483824275","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483824275?lang=zh_cn&edition=full","pubTime":"2024-11-14 18:30","pubTimestamp":1731580257,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)公告，公司收到国家药品监督管理局核准签发的达格列净原料药《化学原料药上市申请批准通知书》。相关药品适应症：在饮食和运动基础上，本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。本品不适用于治疗1型糖尿病或糖尿病酮症酸中毒。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211030.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4017","301201","BK0239","CDE"],"gpt_icon":0},{"id":"2483824044","title":"诚达药业最新公告：达格列净原料药通过CDE审批","url":"https://stock-news.laohu8.com/highlight/detail?id=2483824044","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483824044?lang=zh_cn&edition=full","pubTime":"2024-11-14 18:30","pubTimestamp":1731580244,"startTime":"0","endTime":"0","summary":"诚达药业公告，公司收到国家药监局核准签发的达格列净原料药《化学原料药上市申请批准通知书》。达格列净原料药通过CDE技术审评。在饮食和运动基础上，该药品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400030805.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"gpt_icon":0},{"id":"2483848824","title":"诚达药业：达格列净原料药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2483848824","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483848824?lang=zh_cn&edition=full","pubTime":"2024-11-14 18:28","pubTimestamp":1731580124,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2481528757","title":"诚达药业(301201.SZ)累计回购2.1%股份 耗资5706.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481528757","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481528757?lang=zh_cn&edition=full","pubTime":"2024-11-05 16:06","pubTimestamp":1730793995,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)发布公告，截至2024年10月31日，公司通过回购专用证券账户以集中竞价交易方式已累计回购公司股份324.47万股，占公司目前总股本的比例为2.1%，最高成交价为22.21元/股，最低成交价为14.63元/股，交易总金额为5706.16万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1206820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2479612282","title":"诚达药业（301201）2024年三季报简析：净利润减33.98%，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2479612282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479612282?lang=zh_cn&edition=full","pubTime":"2024-10-30 06:36","pubTimestamp":1730241371,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诚达药业发布2024年三季报。截至本报告期末，公司营业总收入2.44亿元，同比下降6.34%，归母净利润4039.28万元，同比下降33.98%。按单季度数据看，第三季度营业总收入7975.65万元，同比下降14.85%，第三季度归母净利润1521.8万元，同比下降52.19%。本报告期诚达药业公司应收账款体量较大，当期应收账款占最新年报归母净利润比达78.65%。然而去年的净利率为21.99%，算上全部成本后，公司产品或服务的附加值高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000007454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201"],"gpt_icon":0},{"id":"2479432718","title":"图解诚达药业三季报：第三季度单季净利润同比减52.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479432718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479432718?lang=zh_cn&edition=full","pubTime":"2024-10-29 01:20","pubTimestamp":1730136021,"startTime":"0","endTime":"0","summary":"证券之星消息，诚达药业2024年三季报显示，公司主营收入2.44亿元，同比下降6.34%；归母净利润4039.28万元，同比下降33.98%；扣非净利润1443.17万元，同比下降59.78%；其中2024年第三季度，公司单季度主营收入7975.65万元，同比下降14.85%；单季度归母净利润1521.8万元，同比下降52.19%；单季度扣非净利润1126.77万元，同比下降43.42%；负债率6.78%，投资收益2381.91万元，财务费用-323.1万元，毛利率43.54%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900000653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201"],"gpt_icon":0},{"id":"2478488775","title":"诚达药业(301201.SZ)发布前三季度业绩，净利润4039.28万元，下降33.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478488775","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478488775?lang=zh_cn&edition=full","pubTime":"2024-10-28 21:02","pubTimestamp":1730120542,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业(301201.SZ)发布2024年三季度报告，该公司前三季度营业收入为2.44亿元，同比减少6.34%。归属于上市公司股东的净利润为4039.28万元，同比减少33.98%。归属于上市公司股东的扣除非经常性损益的净利润为1443.17万元，同比减少59.78%。基本每股收益为0.2654元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1201725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301201"],"gpt_icon":0},{"id":"2478759179","title":"诚达药业(301201)9月30日股东户数1.47万户，较上期减少1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478759179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478759179?lang=zh_cn&edition=full","pubTime":"2024-10-28 17:08","pubTimestamp":1730106534,"startTime":"0","endTime":"0","summary":"证券之星消息，近日诚达药业披露，截至2024年9月30日公司股东户数为1.47万户，较6月30日减少246.0户，减幅为1.65%。在医疗服务行业个股中，诚达药业股东户数低于行业平均水平，截至9月30日，医疗服务行业平均股东户数为4.49万户。从股价来看，2024年6月30日至2024年9月30日，诚达药业区间涨幅为21.12%，在此期间股东户数减少246.0户，减幅为1.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800022835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2477430246","title":"诚达药业：10月23日接受机构调研，国信证券、跬步投资等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2477430246","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477430246?lang=zh_cn&edition=full","pubTime":"2024-10-23 18:42","pubTimestamp":1729680131,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年10月23日诚达药业发布公告称公司于2024年10月23日接受机构调研，国信证券朱钰波 朱晔 汪雅雯 苏于 马佳涛 孔柯卿、跬步投资高原 陈帆、农行嘉兴分行顾志军、高净值客户 郁宏,王开亮,叶岺设,张玲,黄荣春参与。诚达药业主营业务：主要致力于为跨国制药企业及医药研发机构提供关键医药中间体CDMO服务,并从事左旋肉碱系列产品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102300031442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0183","BK0276","BK0239","BK0028","002736","301201"],"gpt_icon":0},{"id":"2477802735","title":"10月22日诚达药业现1笔折价21.48%的大宗交易 合计成交712.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477802735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477802735?lang=zh_cn&edition=full","pubTime":"2024-10-22 16:48","pubTimestamp":1729586937,"startTime":"0","endTime":"0","summary":"证券之星消息，10月22日诚达药业发生大宗交易，交易数据如下：大宗交易成交价格16.96元，相对当日收盘价折价21.48%，成交42万股，成交金额712.32万元，买方营业部为国投证券股份有限公司嘉兴嘉善施家南路证券营业部，卖方营业部为国投证券股份有限公司嘉兴嘉善施家南路证券营业部。近三个月该股共发生4笔大宗交易，合计成交1.49万手，折价成交4笔。截至2024年10月22日收盘，诚达药业报收于21.6元，上涨1.89%，换手率2.98%，成交量2.6万手，成交额5585.38万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102200025746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"gpt_icon":0},{"id":"2477309839","title":"诚达药业10月21日现1笔大宗交易 成交金额403.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477309839","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477309839?lang=zh_cn&edition=full","pubTime":"2024-10-21 17:00","pubTimestamp":1729501200,"startTime":"0","endTime":"0","summary":" 10月21日，诚达药业收涨0.95%，收盘价为21.20元，发生1笔大宗交易，合计成交量24万股，成交金额403.2万元。 进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为1789.42万元。该股近5个交易日累计上涨0.76%，主力资金合计净流出936.25万元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-21/doc-incticef5619738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","301201"],"gpt_icon":0},{"id":"2475330529","title":"10月14日诚达药业现1笔折价21.91%的大宗交易 合计成交731.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475330529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475330529?lang=zh_cn&edition=full","pubTime":"2024-10-14 16:52","pubTimestamp":1728895945,"startTime":"0","endTime":"0","summary":"证券之星消息，10月14日诚达药业发生大宗交易，交易数据如下：大宗交易成交价格16.43元，相对当日收盘价折价21.91%，成交44.5万股，成交金额731.14万元，买方营业部为国投证券股份有限公司嘉兴嘉善施家南路证券营业部，卖方营业部为国投证券股份有限公司嘉兴嘉善施家南路证券营业部。近三个月该股共发生1笔大宗交易，合计成交4450.0手，折价成交1笔。截至2024年10月14日收盘，诚达药业报收于21.04元，上涨2.48%，换手率2.41%，成交量2.1万手，成交额4364.37万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101400020591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-20","address":"浙江省嘉兴市嘉善县惠民街道黄河路36号","stockEarnings":[{"period":"1week","weight":-0.066},{"period":"1month","weight":-0.0315},{"period":"3month","weight":0.2938},{"period":"6month","weight":0.1381},{"period":"1year","weight":-0.1328},{"period":"ytd","weight":-0.1331}],"companyName":"诚达药业股份有限公司","boardCode":"AI0027","perCapita":"5950股","boardName":"医药制造业","registeredCapital":"15471万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":" 诚达药业股份有限公司主要致力于为跨国制药企业及医药研发机构提供关键医药中间体、原料药CDMO服务，并从事左旋肉碱系列产品的研发、生产和销售。公司主要产品及服务是预临床及临床阶段新药CDMO服务、已上市药物CDMO服务、仿制药中间体CDMO服务、食品添加剂、饲料添加剂、原料药。公司是国内最早实现左旋肉碱系列产品产业化的企业之一，也是全球左旋肉碱主要供应商之一。产品产业链齐全，包括食品添加剂、饲料添加剂、原料药，产品出口全球30多个国家和地区。","serverTime":1734698102733,"listedPrice":72.69,"stockholders":"14654人(较上一季度减少1.65%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诚达药业,301201,诚达药业股票,诚达药业股票老虎,诚达药业股票老虎国际,诚达药业行情,诚达药业股票行情,诚达药业股价,诚达药业股市,诚达药业股票价格,诚达药业股票交易,诚达药业股票购买,诚达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}